drugset
drugset / Trial / NCT00768339

A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

NCT00768339 ↗

Phase 1/2 Terminated 25 enrolled Aegera Therapeutics The Leukemia and Lymphoma Society · collab
NaSingle-groupOpen-labelTreatment

Summary

AEG35156 has shown early evidence of activity in patients with advanced indolent B-cell lymphomas in Phase 1 trials and merits further evaluation in this disease. This trial is designed to determine the recommended dose of AEG35156 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and indolent B-cell lymphomas.

Timeline

Start
2008-09
Primary completion
2011-06
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AEG35156 Antisense oligonucleotide 50 mg Intravenous
Subject AEG35156 Antisense oligonucleotide 100 mg Intravenous
Subject AEG35156 Antisense oligonucleotide 150 mg Intravenous
Subject AEG35156 Antisense oligonucleotide 200 mg Intravenous
Subject AEG35156 Antisense oligonucleotide 250 mg Intravenous
Subject AEG35156 Antisense oligonucleotide 300 mg Intravenous

Indications

B-cell chronic lymphocytic leukemia